C9031 — Lutetium lu 177, dotatate, therapeutic, 1 mci
C9031 is a HCPCS Level II code for lutetium lu 177, dotatate, therapeutic, 1 mci. It belongs to the Outpatient Prospective Payment System section. It was terminated on December 31, 2018 and is not valid on new claims.
This code has been terminated
CMS terminated C9031 on December 31, 2018. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9031
- Long descriptor
- Lutetium lu 177, dotatate, therapeutic, 1 mci
- Short descriptor
- Lutetium lu 177 dotatate, tx
- Added
- July 1, 2018
- Terminated
- December 31, 2018
- BETOS
- O1D
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9031
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9031 is not quite right, the correct code is very often within a few positions of it.
- C9023Injection, testosterone undecanoate, 1 mgterminated
- C9024Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabineterminated
- C9025Injection, ramucirumab, 5 mgterminated
- C9026Injection, vedolizumab, 1 mgterminated
- C9027Injection, pembrolizumab, 1 mgterminated
- C9028Injection, inotuzumab ozogamicin, 0.1 mgterminated
- C9029Injection, guselkumab, 1 mgterminated
- C9030Injection, copanlisib, 1 mgterminated
- C9032Injection, voretigene neparvovec-rzyl, 1 billion vector genometerminated
- C9033Injection, fosnetupitant 235 mg and palonosetron 0.25 mgterminated
- C9034Injection, dexamethasone 9%, intraocular, 1 mcgterminated
- C9035Injection, aripiprazole lauroxil (aristada initio), 1 mgterminated
- C9036Injection, patisiran, 0.1 mgterminated
- C9037Injection, risperidone (perseris), 0.5 mgterminated
- C9038Injection, mogamulizumab-kpkc, 1 mgterminated
- C9039Injection, plazomicin, 5 mgterminated
Questions about C9031
What is HCPCS code C9031?
C9031 is a HCPCS Level II code for lutetium lu 177, dotatate, therapeutic, 1 mci. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9031?
The CMS HCPCS file marks C9031 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9031 still valid?
No. C9031 was terminated on December 31, 2018 and should not be used on new claims.